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Abstract
The nuclear export protein Chromosome Maintenance Region 1, found elevated in NonHodgkin's Lymphoma, controls localization of critical tumor suppressor proteins.
Nuclear localization of tumor suppressor proteins is necessary for their cell surveillance function. However, their nuclear exclusion by Chromosome maintenance region 1 renders them ineffective making this nuclear transporter an attractive therapeutic target.
We have identified selective inhibitors of nuclear export that lock tumor suppressor proteins in the cell nucleus leading to apoptosis of lymphoid but not normal cells. Our 
Introduction:
Despite the advancements in our understanding and classification of the disease as well as the introduction of the R-CHOP regimen, Non-Hodgkin's Lymphomas (NHL) remain deadly diseases, with ~200,000 annual deaths globally 1 . These statistics show that newer, molecular based therapeutic modalities are urgently needed. Most anti-cancer drugs target nuclear retention of TSPs such as p53 family proteins 2 , FOXO 3 and p27 4 .
However, mislocalization of these and other TSPs by over-expression of the nuclear export protein CRM1 in cancer cells leads to their functional inactivation 5 . Nuclear exclusion of TSP, mediated by CRM1, is now appreciated as a significant mechanism of therapy resistance by malignant cells 6 . Here, we report a novel strategy to overcome these CRM1 mediated effects in NHL.
CRM1 is a member of the importin β superfamily of nuclear transport receptors, recognizing proteins bearing a leucine-rich nuclear export sequence (NES) 7 . There are seven known nuclear export proteins, but CRM1 mediates the export of nearly all major TSPs out of the nucleus. Nuclear exclusion of p53 family proteins, FOXO, p27, and other
TSPs by CRM1 render cancer cells resistant to apoptosis by different therapies 8 . Forced nuclear retention of TSPs by inhibition of CRM1 (without affecting their nuclear import)
leads to restoration of their tumor suppressing activities and prevents their proteasome mediated degradation in the cytoplasm 9 . Nuclear localization with functional activation of TSP has been shown to lead to selective elimination of tumor cells 10 . Inhibition of CRM1 is one approach to restore nuclear localization and activation of multiple TSPs, allowing them to function properly and induce cancer specific apoptosis.
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Earlier approaches to target CRM1 lead to the development of Leptomycin B 11 which proved to have limited clinical applicability due to associated toxicity and minimal efficacy 12 . Semi-synthetic derivatives of LMB with improved pharmacologic properties showed enhanced therapeutic indices in animals indicating that the side effects of LMB were due to off-target effects 13 ; these agents have not entered clinical studies. A novel small molecule reversible inhibitor of CRM1 was also reported to have activity against multiple myeloma 14 . This suggests that newer CRM1 inhibitors with high specificity, cancer cell selectivity and low toxicity are needed.
Using high throughput screening and structure-based drug design, we have developed a highly specific small molecule inhibitor of CRM1 that irreversibly binds to the putative target protein NES recognizing Cys-528 residue (Supplementary Figure 1 and Figure 1A ).
This results in locking of TSPs in the nucleus of cancer cells leading to selective apoptosis in solid tumors 15, 16 and hematological malignancies 17, 18 . In this proof of concept report, we investigated the anti-cancer potential of KPT SINEs against NHL cell lines and corresponding xenograft models. Our data demonstrate that NHL cell selectivity of KPT SINEs is due in part to nuclear retention of major TSPs including p53/p73 that is not induced in normal cells. Our findings can potentially be translated towards clinical application of SINEs against NHL. 21 .
Materials and Methods
WSU
Western Blot and Immunoprecipitation Analysis: 1x10 6 cells were grown in 6 well petri plates and exposed to indicated concentrations of KPT-185 for 24 hrs followed by extraction of nuclear and cytosolic protein for western blot analysis. Preparation of cellular lysates, protein concentration determination immunoprecipitation assay and SDS-PAGE analyses were performed as previously described 21 .
Immunofluorescence and p53 and p73 Cellular Staining:
For protein localization experiments, 1x10 6 cells were grown in 24 well plates and exposed to KPT-185 at indicated concentrations for 24 hrs. At the end of the treatment 7 the cells were mounted on glass slides using cytospin (2500 rpm for 10 seconds twice)
followed by fixing with 10% paraformaldehyde for 20 min. The fixed slides permeabilized using 0.5% Triton (Sigma, St Louis USA) and were blocked in 0.2% horse serum for 45 minutes. The slides were probed with primary and secondary antibody according to our previously published methods 22 . The slides were dried, mounting medium added and were covered with coverslips before analysis under an inverted 3 color (DAPI, GFP and RFP) fluorescent microscope.
siRNA and Transfections
To study the effect of p53/p73 silencing on activity of KPT-185, we utilized siRNA 
p53-DNA Binding and Transcriptional Activation by KPT-185
In order to investigate p53 DNA binding, electromobility shift assay (EMSA) was 
Development of Animal Xenografts and Pre-clinical Efficacy Trial
Mouse xenografts were established as described previously 24 . In summary, four-weekold female ICR-SCID female mice were obtained from Taconic Laboratory and 150 mg/kg or KPT-251 at 25 and 75 mg/kg s.c. daily for 2 weeks. CHOP regimen was used as positive control at MTD as described previously 25 . Mice in the control and KPT-SINE treated groups were followed for measurement of s.c. tumors, changes in body weight, and other side effects of the drugs. Tumors were measured twice weekly.
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Tumor weight (mg) was calculated using the formula: (A × B 2 ) / 2, where A and B are the tumor length and width (mm). To avoid discomfort and in keeping with our IACUC procedures, animals were euthanized when their total tumor burden reached 2,000 mg.
All studies involving mice were done under Animal Investigation Committee-approved protocols.
Immunohistochemical Determination of Tumor Markers
The expression of p73 was detected in histologic sections of tumor xenografts. Sections were cut from formalin-fixed, paraffin-embedded tissue blocks, collected on 3-ethoxyaminoethyl-silane-treated slides, and allowed to dry overnight at 37°C. Sections were dewaxed in xylene, rehydrated through graded concentrations of ethanol to distilled water, immersed in 10 mmol/L citrate buffer (pH 6.0), and processed in a thermostatic water bath for 40 min at 98°C for antigen retrieval. Anti-p73 and ki67 incubations were done overnight at room temperature in a humidified atmosphere followed by a 30-min incubation of secondary antibody. Slides were then incubated with streptavidin peroxidase and visualized using the 3,3′-diaminobenzidine chromogen (Lab Vision).
Tumor Tissue Proteins Isolation and Western Blot Analysis
At the end of the treatment period tumors were excised and one part was minced in proteins isolation buffer using our well established methods 26 . 50 µ g of tumor lysates
were resolved using western blotting assay. The membranes were probed for p73, Bax and β-actin. All tumor tissue western blots experiments were performed in triplicates. Figure 2) . Most significantly the drugs showed negligible cytotoxicity on PBLs (IC 50 >20 µM). Reduction in viability was associated with CRM1 inhibitory activity, as KPT-TRANS, which lacks significant SINE activity, did not induce statistically significant growth inhibition. LMB had somewhat similar growth inhibitory profile as the SINE compounds.
Results
KPT-SINE Induces Growth Inhibition in NHL Cell
KPT SINEs Induce Apoptosis in Lymphoma but Not Normal Cells
Activation of TSPs is believed to induce a 'genome survey' and lead to the repair or apoptosis of cells with damaged DNA; normal cells are spared. Because CRM1 is the major exporter of TSPs, and their nuclear export inactivates their tumor suppressing function, we investigated whether inhibition of CRM1 induce apoptosis in the NHL cell lines by using Annexin V FITC and Histone DNA ELISA assay. As expected and in line with the growth inhibition results, SINEs induced apoptosis in WSU FSCCL (>80% at 100 nM), WSU-DLCL2 (>75% at 100 nM) and WSU-WM (>50% at 100 nM) cell lines while sparing PBLs, which showed no apoptosis up to 2 microM (Figure 2A) .
Additionally, we also tested apoptosis induction using Histone/DNA ELISA assay and similar to Annexin V FITC results comparable apoptosis was observed ( Figure 2B ). The inactive analog KPT-TRANS did not induce apoptosis in the tested cell lines. Together, the data presented thus far demonstrate the anti-cancer potential of SINEs as new class of compounds which are cytotoxic for NHL and not PBLs.
Major TSPs are Target of KPT-SINEs
In order to delineate the molecular mechanisms of cancer cell apoptosis induction by CRM1 inhibitors in greater detail, nuclear localization of different TSPs were investigated using western blot analysis and fluorescence microscopy. As shown in Figure 3A , exposure of NHL cells to increasing concentrations of KPT-185 (0-50 nM) resulted in progressive increase in nuclear fraction of major TSPs FOXO3a, p53, p73, p27 and p21 in both WSU-FSCCL (wt-p53) and WSU-DLCL 2 (mut-p53). Similary, we observed activation of both p53 and p73 protein and mRNA expression in WSU-FSCCL
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and WSU-DLCL2 cell lines respectively (Supplementary Figure 3) . To the contrary, KPT-185 exposure did not result in any significant activation of p53/p73 in normal PBLs at similar concentrations ( Figure 3B ). We also evaluated p53 and p73 nuclear retention using an immunofluorescence assay. As can be seen in Figure 3C , 
TSP Knockdown by RNA Interference Abrogates KPT SINE Activity
In order to determine whether SINE-induced apoptosis was mediated primarily through p53 or p73, we investigated the effect of either p53 siRNA in wt-and p73 siRNA in mutcell lines on the activity of KPT-185. As can be seen in Figure 4A , siRNA knockdown of p53 and/or p73 markedly reduced apoptosis by KPT-185 in WSU-FSCCL and WSU-DLCL2 cell lines respectively (Histone DNA ELISA assay). Western blotting experiments on siRNA treated cells showed down-regulation of p53 and p73. Of paramount significance is the observation that in addition to p53 and or p73, siRNA silencing showed downregulation of common downstream effector pathway molecules such as cell cycle regulator p21 and pro-apoptotic Bax (Figure 4 B) . We also evaluated the effect of p53 and p73 siRNA on cell cycle regulation (a target of activated p53 and p73) by KPT-SINEs. As can be seen from results of Figure 4C , in the absence of siRNA, KPT-185 treatment resulted in enhancement of G0-G1 cell cycle accumulation (Trans-KPT and LMB were used used as negative and positive control respectively). However, in the presence of p53 siRNA in WSU-FSCCL and p73 siRNA in WSU-DLCL2, the KPT-815 was not effective in inducing G0-G1 ( Figure 4C ). These results are further in support of the primary role of p53 family members in KPT-SINE-mediated activity.
KPT-SINE Promote Cancer Cell Selective p53 DNA Binding
Activated p53 requires not only nuclear localization but also sequence specific DNA binding. In order to verify whether SINEs can promote nuclear localization of p53 in NHL cells, electromobility shift assays (EMSA) p53-DNA binding assays, and p53 transcription activation assays were performed. As shown in Figure 5A , SINE treatment resulted in enhancement of p53-DNA binding. At similar doses of SINEs, there was no statistically significant p53 DNA binding in PBLs, highlighting an NHL specific p53
effect. Further, a highly specific p53 transcription activation assay was utilized to validate p53 transcriptional activation in WSU-FSCCL and PBLs. As can be seen from results of lysates showed similar trend with emergence of p73 and pro-apoptotic Bax ( Figure 6D ).
Taken together, these results fortify our hypothesis that the anti-cancer activity of SINEs is due at least in part to the intra-tumoral activation of p53 family proteins.
Discussion
In Apart from Leptomycin B (LMB), there have not been any serious attempts to develop targeted inhibitors against CRM1. LMB is a Streptomyces metabolite that covalently attaches to the sulfhydryl group of cysteine at position 528 in CRM1 and thereby prohibits CRM1 from associating with NES-containing cargo 32 . As a natural product, LMB has very poor pharmaceutical properties, must be given parenterally, and has poor selectivity for cancer versus normal cells. It showed marked toxicity in mice, and similar toxicities in humans. Such promiscuity of this drug may be through weak associations with secondary proteins other than CRM1 resulting in unwanted side effects. This is a common phenomenon observed with most natural agent derived drugs. The semisynthetic, parenteral derivatives of LMB with improved pharmacological properties show improved therapeutic windows in mouse cancer models. However, its clinical utility is yet to be verified. A reversible, orally bioavailable CRM1 inhibitor CBS9106 has been reported to have anti-myeloma activity but its developmental status is unknown 14 .
Our As CRM1 inhibition forces the nuclear localization of many TSPs, delineation of which specific growth regulators may be involved in SINE-induced cytotoxicity is important.
Here, we showed that in addition to FOXO, p27 and p21, siRNA silencing of p53 in wtor p73 in mut-p53 cell lines abrogates SINE CRM1 antagonist functional TSP activation and downstream cytotoxicity in vitro. These findings indicate that in NHL, forced nuclear retention of TSPs in general and p53 and/or p73 in specific may be critical to the antilymphoma activity of SINE compounds. Moreover, these data show that SINE compounds should have activity across multiple genotypes, including NHL with p53 mutations. Our data in both WSU-DLCL2 and WSU-WM confirm this broad activity, and implicate p73 in apoptosis induction in tumors harboring p53 mutations. As nuclear export is essential for normal cell homeostasis, it was critical to assess the tolerability of systemic administration of SINE CRM1 antagonists in animals. Along these lines, we observed that oral or s.c. administration of SINE is well tolerated at doses that have significant anti-tumor activity. Moreover, the efficacy of SINE was associated with the activation of p73 signaling in the tested tumors in vivo ( Figure 6A -C) confirming the in vitro findings.
In conclusion, we have rationally designed small molecule, drug-like SINE CRM1
antagonists, and performed in vitro and in vivo evaluations to demonstrate their antilymphoma potential using multiple NHL models. Additionally, we have provided strong evidence in support of SINEs action that involves nuclear retention of p53 family proteins. Based on these provocative pre-clinical studies, we anticipate that SINEs will be evaluated in the clinic against NHL and other hematologic malignancies in the near future.
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